Forte Biosciences Inc.
09/08/2026 | Press release | Distributed by Public on 09/08/2026 15:06
Termination Notice (Form 15-12G)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-38052
Forte Biosciences, Inc.
(Exact name of registrant as specified in its charter)
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
(310) 618-6994
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Preferred Stock Purchase Rights
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒
|
|
|
Rule 12g-4(a)(2)
|
☐
|
|
|
Rule 12h-3(b)(1)(i)
|
☐
|
|
|
Rule 12h-3(b)(1)(ii)
|
☐
|
|
|
Rule 15d-6
|
☐
|
|
|
Rule 15d-22(b)
|
☐
|
Approximate number of holders of record as of the certification or notice date: 0.
Pursuant to the requirements of the Securities Exchange Act of 1934, Forte Biosciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
Forte Biosciences, Inc.
|
||
|
Date: September 8, 2026
|
By:
|
/s/ Hemamalini (Malini) Moorthy
|
| Name: Hemamalini (Malini) Moorthy | ||
| Title: Vice President and Secretary | ||
Forte Biosciences Inc. published this content on September 08, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 08, 2026 at 21:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]